Milan S Geybels1,2, Karen D McCloskey3, Ian G Mills3, Janet L Stanford1,4. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. 3. Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK. 4. Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Calcium channel blockers (CCBs) may affect prostate cancer (PCa) growth by various mechanisms including those related to androgens. The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tumors that harbor the gene fusion are believed to represent a distinct disease subtype. We studied the association of CCB use with the risk of PCa, and molecular subtypes of PCa defined by T2E status. METHODS: Participants were residents of King County, Washington, recruited for population-based case-control studies (1993-1996 or 2002-2005). Tumor T2E status was determined by fluorescence in situ hybridization using tumor tissue specimens from radical prostatectomy. Detailed information on use of CCBs and other variables was obtained through in-person interviews. Binomial and polytomous logistic regression were used to generate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The study included 1,747 PCa patients and 1,635 age-matched controls. A subset of 563 patients treated with radical prostatectomy had T2E status determined, of which 295 were T2E positive (52%). Use of CCBs (ever vs. never) was not associated with overall PCa risk. However, among European-American men, users had a reduced risk of higher-grade PCa (Gleason scores ≥7: adjusted OR = 0.64; 95% CI: 0.44-0.95). Further, use of CCBs was associated with a reduced risk of T2E positive PCa (adjusted OR = 0.38; 95% CI: 0.19-0.78), but was not associated with T2E negative PCa. CONCLUSIONS: This study found suggestive evidence that use of CCBs is associated with reduced relative risks for higher Gleason score and T2E positive PCa. Future studies of PCa etiology should consider etiologic heterogeneity as PCa subtypes may develop through different causal pathways. Prostate 77:282-290, 2017.
BACKGROUND:Calcium channel blockers (CCBs) may affect prostate cancer (PCa) growth by various mechanisms including those related to androgens. The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tumors that harbor the gene fusion are believed to represent a distinct disease subtype. We studied the association of CCB use with the risk of PCa, and molecular subtypes of PCa defined by T2E status. METHODS:Participants were residents of King County, Washington, recruited for population-based case-control studies (1993-1996 or 2002-2005). Tumor T2E status was determined by fluorescence in situ hybridization using tumor tissue specimens from radical prostatectomy. Detailed information on use of CCBs and other variables was obtained through in-person interviews. Binomial and polytomous logistic regression were used to generate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The study included 1,747 PCa patients and 1,635 age-matched controls. A subset of 563 patients treated with radical prostatectomy had T2E status determined, of which 295 were T2E positive (52%). Use of CCBs (ever vs. never) was not associated with overall PCa risk. However, among European-American men, users had a reduced risk of higher-grade PCa (Gleason scores ≥7: adjusted OR = 0.64; 95% CI: 0.44-0.95). Further, use of CCBs was associated with a reduced risk of T2E positive PCa (adjusted OR = 0.38; 95% CI: 0.19-0.78), but was not associated with T2E negative PCa. CONCLUSIONS: This study found suggestive evidence that use of CCBs is associated with reduced relative risks for higher Gleason score and T2E positive PCa. Future studies of PCa etiology should consider etiologic heterogeneity as PCa subtypes may develop through different causal pathways. Prostate 77:282-290, 2017.
Authors: Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou Journal: Prostate Date: 2010-09-28 Impact factor: 4.104
Authors: Paula Paulo; Franclim R Ribeiro; Joana Santos; Diana Mesquita; Mafalda Almeida; João D Barros-Silva; Harri Itkonen; Rui Henrique; Carmen Jerónimo; Anita Sveen; Ian G Mills; Rolf I Skotheim; Ragnhild A Lothe; Manuel R Teixeira Journal: Neoplasia Date: 2012-07 Impact factor: 5.715
Authors: Rebecca E Graff; Andreas Pettersson; Rosina T Lis; Thomas U Ahearn; Sarah C Markt; Kathryn M Wilson; Jennifer R Rider; Michelangelo Fiorentino; Stephen Finn; Stacey A Kenfield; Massimo Loda; Edward L Giovannucci; Bernard Rosner; Lorelei A Mucci Journal: Am J Clin Nutr Date: 2016-01-27 Impact factor: 7.045
Authors: J L Wright; L Chéry; S Holt; D W Lin; M Luedeke; A E Rinckleb; C Maier; J L Stanford Journal: Prostate Cancer Prostatic Dis Date: 2015-10-27 Impact factor: 5.554
Authors: Milan S Geybels; Joshi J Alumkal; Manuel Luedeke; Antje Rinckleb; Shanshan Zhao; Irene M Shui; Marina Bibikova; Brandy Klotzle; Piet A van den Brandt; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Christiane Maier; Janet L Stanford Journal: Clin Epigenetics Date: 2015-12-12 Impact factor: 6.551
Authors: Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff Journal: Adv Cancer Res Date: 2020-07-09 Impact factor: 6.242
Authors: Dana Hashim; Amparo G Gonzalez-Feliciano; Thomas U Ahearn; Andreas Pettersson; Lauren Barber; Claire H Pernar; Ericka M Ebot; Masis Isikbay; Stephen P Finn; Edward L Giovannucci; Rosina T Lis; Massimo Loda; Giovanni Parmigiani; Tamara Lotan; Philip W Kantoff; Lorelei A Mucci; Rebecca E Graff Journal: Int J Cancer Date: 2019-07-27 Impact factor: 7.396
Authors: Alana L Cutliffe; Sharon L McKenna; Darshan S Chandrashekar; Alvin Ng; Ginny Devonshire; Rebecca C Fitzgerald; Tracey R O'Donovan; John J Mackrill Journal: Explor Target Antitumor Ther Date: 2021-12-31